The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten

Altus Pharmaceuticals (NASDAQ: [[ticker:ALTU]])
Cash on hand: $8.1 million
Related Xconomy coverage:
“Altus Pharma to Shut Doors”
“Altus Cuts 75 Percent of Staff”

AMAG Pharmaceuticals (NASDAQ: [[ticker:AMAG]])
Cash on hand: $175 million
Related Xconomy coverage:
“AMAG Pharmaceuticals Wins FDA Approval to Sell Iron Deficiency Drug”

Antigenics (NASDAQ: [[ticker:AGEN]])
Cash on hand: $21.1 million
Related Xconomy coverage:
“Riding Dendreon’s Coattails, Antigenics and Oncothyreon Shares Soar”
“Antigenics, Digging Through Old Data, Sees Survival Edge For Cancer Vaccine”
“Antigenics Asks European Regulators to Approve Oncophage For Kidney Cancer”

Ariad Pharmaceuticals (NASDAQ: [[ticker:ARIA]])
Cash on hand: $39.5 million
Related Xconomy coverage:
“Ariad Directors Resign En Masse, Accuse CEO of Grossly Inappropriate Behavior”
“Ariad Pharmaceuticals Edging Toward Becoming a Commercial Cancer Drug Company”
“Ariad CEO Fires Back at Resigning Directors and Their ‘False and Misleading’ Attacks”
“Ariad Raises $30.9M”

ArQule (NASDAQ: [[ticker:ARQL]])
Cash on hand: $185.7 million
Related Xconomy coverage:
“ArQule Snags $60M From Daiichi Sankyo”
“ArQule Gets a New CEO”

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button. For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. *Price is subject to change without notice

Biogen Idec (NASDAQ: [[ticker:BIIB]])
Cash on hand: $1.62 billion
Related Xconomy coverage:
“Biogen Idec Makes Hostile $350M Takeover Bid for Facet Biotech”
“Icahn Throws Down the Gloves, Attacks Biogen Idec’s ‘Failed Leadership‘”
“Biogen Idec Pipeline Strong, Tysabri Coming Back, Icahn Would Weaken Board, Company Says”
“Biogen Idec Research Boss Quits Board, Giving Icahn Shot at Pushing R&D Agenda”
“Biogen Idec Tysabri Sales Fall Shy of Street Expectations”

Boston Scientific (NYSE: [[ticker:BSX]])
Cash on hand: $1.19 billion
Related Xconomy coverage:
“Boston Scientific CEO Retires, Replaced By Former Zimmer Boss”
“Boston Scientific Pays $716M to Settle Patent Dispute With J&J”

Bruker (NASDAQ: [[ticker:BRKR]])
Cash on hand: $152.6 million

Caliper Life Sciences (NASDAQ: [[ticker:CALP]])
Cash on hand: $23.5 million
Related Xconomy coverage:
“Caliper Bets Future on Tools That Light Up Genes Before Researchers’ Eyes”

Celldex Therapeutics (NASDAQ: [[ticker:CLDX]])
Cash on hand: $31.6 million
Related Xconomy coverage:
“Avant Changes Name to Celldex Therapeutics, Hires Marucci as Permanent CEO”

Charles River Labs (NYSE: [[ticker:CRL]])
Cash on hand: $154.8 million

Clinical Data (NASDAQ: [[ticker:CLDA]])
Cash on hand: $52.4 million
Related Xconomy coverage:
“Clinical Data Touts Positive Results for Anti-Depressant“